The State supports seven new pharmaceutical investment projects to “relocalize the production of essential medicines” in France

The seven projects are supported by France 2030 as part of the plan to relocalize essential medicines, announced by Emmanuel Macron in June 2023.

Objective : “reconquer the health sovereignty of France”. Seven new industrial investment projects in the French pharmaceutical sector will be supported by the France 2030 program, the government announced Monday January 6.

The selected industrial projects, located throughout France, are “so many stones brought to the building of our health sovereignty”assured four ministers in a joint press release: Catherine Vautrin (Labor, Health, Solidarity and Families), Eric Lombard (Economy), Yannick Neuder (Health) and Marc Ferracci (Industry).

The seven projects are chosen as part of the relocation plan for essential medicines announced by Emmanuel Macron in June 2023, and are added to seven other projects already supported. “Nearly 50 million euros of public support have been mobilized by France 2030, to realize nearly 300 million euros of industrial investments”details the press release, “in return for commitments from manufacturers to secure supplies to the French market”.

Among the investments supported, most will allow the companies concerned to increase their production. This is the case of Delpharm Lille, “specialized in the manufacturing and packaging of solid hormonal, highly active and oncological products (tablets and capsules), from Delpharm Tours, “specialized in sterile and aseptic production of ampoules, bottles, eye drops and syringes”, or even Zach System, a producer of active ingredients which will be able to increase its production and respond to “needs of the French State during situations of tension”.

Adhex Pharma will also be able to increase its production of “essential medicines (orodispersible patches and films)” and repatriate it from Germany to France, while Benta Lyon will be able “develop its portfolio of generic medicines (…) manufactured in France”et “commits to producing pediatric paracetamol oral suspension on its French site”a drug that has experienced supply tensions in recent years.

Ipsophene, a company founded in Toulouse in 2021, will work to create paracetamol manufacturing processes expected to reduce production costs and the volumes of waste produced, while NextPharma plans “create a new manufacturing area dedicated to non-sterile liquids, in particular to ensure the production of Levetiracetam”an antiepileptic drug.